Kelly Deck - 01 Apr 2025 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Reporting relationship: Chief Financial Officer
Issuer ticker: INBX
Reported as of: 01 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2025, 16:39:28 UTC
Prior SEC filing: 30 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Kelly Deck

Key filing fact

Kelly Deck filed Form 4 for Inhibrx Biosciences, Inc. (INBX) on 02 Apr 2025.

Key facts

This page summarizes Kelly Deck's Form 4 filing for Inhibrx Biosciences, Inc. (INBX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2025, 16:39.

Change

Previous filing in this sequence was filed on 30 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 01 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $14.05
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on April 1, 2026, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.